



## ASX Announcement

14 November 2024

### Withdrawal of Resolutions at 2024 Annual General Meeting

SYDNEY Australia, 14 November 2024 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) advises that the Board has withdrawn Resolutions 3 and 4 (the **Resolutions**) from the agenda of the Annual General Meeting of shareholders scheduled for 10:00am (AEDT) on Friday, 15 November 2024.

Resolution 3 requested the approval for the for an additional 10% placement facility under ASX Listing Rule 7.1A and Resolution 4 requested Amendments to the Company's Constitution.

The withdrawal of Resolutions 3 and 4 will not affect the validity of the proxy form attached to the Notice of Annual General Meeting or any proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval.

*This announcement was authorised by the Managing Director & CEO on behalf of the Board.*

~ ENDS ~

#### For more information, please contact:

##### John Kelly

Managing Director & CEO

e. [john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)

p. +61 401 922 279

##### Investor Queries

[investorqueries@atomodiagnostics.com](mailto:investorqueries@atomodiagnostics.com)

#### About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)